419 related articles for article (PubMed ID: 17762903)
41. Rituximab, B-lymphocyte depletion, and beta-cell function.
Nagafuchi S; Katsuta H; Anzai K
N Engl J Med; 2010 Feb; 362(8):761; author reply 761. PubMed ID: 20181981
[No Abstract] [Full Text] [Related]
42. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma.
Martin P; Furman RR; Ruan J; Elstrom R; Barrientos J; Niesvizky R; Coleman M; Leonard JP
Semin Hematol; 2008 Apr; 45(2):126-32. PubMed ID: 18381108
[TBL] [Abstract][Full Text] [Related]
43. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases.
Cooper N; Arnold DM
Br J Haematol; 2010 Apr; 149(1):3-13. PubMed ID: 20151975
[TBL] [Abstract][Full Text] [Related]
44. Rituximab for myasthenia gravis: three case reports and review of the literature.
Stieglbauer K; Topakian R; Schäffer V; Aichner FT
J Neurol Sci; 2009 May; 280(1-2):120-2. PubMed ID: 19272616
[TBL] [Abstract][Full Text] [Related]
45. FDA approves new kind of lymphoma treatment. Food and Drug Administration.
James JS; Dubs G
AIDS Treat News; 1997 Dec; (No 284):2-3. PubMed ID: 11364912
[TBL] [Abstract][Full Text] [Related]
46. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients.
Lovric S; Erdbruegger U; Kümpers P; Woywodt A; Koenecke C; Wedemeyer H; Haller H; Haubitz M
Nephrol Dial Transplant; 2009 Jan; 24(1):179-85. PubMed ID: 18685144
[TBL] [Abstract][Full Text] [Related]
47. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse.
Levesque MC; St Clair EW
J Allergy Clin Immunol; 2008 Jan; 121(1):13-21; quiz 22-3. PubMed ID: 18206502
[TBL] [Abstract][Full Text] [Related]
48. Use of rituximab, the new FDA-approved antibody.
Leget GA; Czuczman MS
Curr Opin Oncol; 1998 Nov; 10(6):548-51. PubMed ID: 9818234
[TBL] [Abstract][Full Text] [Related]
49. Clinical images: B cell depletion in the appendix following rituximab treatment.
Paran D; Trej'o L; Caspi D
Arthritis Rheum; 2006 Jul; 54(7):2151. PubMed ID: 16802352
[No Abstract] [Full Text] [Related]
50. B-cell depletion in autoimmune diseases. Advances in autoimmunity.
Guzman Moreno R
Autoimmun Rev; 2009 Jun; 8(7):585-90. PubMed ID: 19393204
[TBL] [Abstract][Full Text] [Related]
51. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.
Perceau G; Diris N; Estines O; Derancourt C; Lévy S; Bernard P
Br J Dermatol; 2006 Nov; 155(5):1053-6. PubMed ID: 17034541
[TBL] [Abstract][Full Text] [Related]
52. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis.
Janas E; Priest R; Wilde JI; White JH; Malhotra R
Clin Exp Immunol; 2005 Mar; 139(3):439-46. PubMed ID: 15730389
[TBL] [Abstract][Full Text] [Related]
53. Long term treatment of rheumatoid arthritis with rituximab.
Caporali R; Caprioli M; Bobbio-Pallavicini F; Bugatti S; Montecucco C
Autoimmun Rev; 2009 Jun; 8(7):591-4. PubMed ID: 19393205
[TBL] [Abstract][Full Text] [Related]
54. B cell monitoring of transplant patients treated with anti-CD20.
Abdallah KO; Prak ET
Clin Transpl; 2006; ():427-37. PubMed ID: 18365400
[TBL] [Abstract][Full Text] [Related]
55. Rituximab in the treatment of bullous systemic lupus erythematosus.
Alsanafi S; Kovarik C; Mermelstein AL; Werth VP
J Clin Rheumatol; 2011 Apr; 17(3):142-4. PubMed ID: 21441817
[TBL] [Abstract][Full Text] [Related]
56. Prospects for B-cell-targeted therapy in autoimmune disease.
Edwards JC; Cambridge G
Rheumatology (Oxford); 2005 Feb; 44(2):151-6. PubMed ID: 15509628
[No Abstract] [Full Text] [Related]
57. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy.
Cravedi P; Ruggenenti P; Sghirlanzoni MC; Remuzzi G
Clin J Am Soc Nephrol; 2007 Sep; 2(5):932-7. PubMed ID: 17702725
[TBL] [Abstract][Full Text] [Related]
58. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
Martin Mdel P; Cravens PD; Winger R; Kieseier BC; Cepok S; Eagar TN; Zamvil SS; Weber MS; Frohman EM; Kleinschmidt-Demasters BK; Montine TJ; Hemmer B; Marra CM; Stüve O
Arch Neurol; 2009 Aug; 66(8):1016-20. PubMed ID: 19667224
[TBL] [Abstract][Full Text] [Related]
59. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
[TBL] [Abstract][Full Text] [Related]
60. Role of rituximab therapy in glomerulonephritis.
Jayne D
J Am Soc Nephrol; 2010 Jan; 21(1):14-7. PubMed ID: 18799717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
